GAINING POUNDS AND APPETITE: STATIN'S DOUBLE-EDGED EFFECT ON PRIMARY PREVENTION

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American journal of preventive cardiology Pub Date : 2024-09-01 DOI:10.1016/j.ajpc.2024.100749
{"title":"GAINING POUNDS AND APPETITE: STATIN'S DOUBLE-EDGED EFFECT ON PRIMARY PREVENTION","authors":"","doi":"10.1016/j.ajpc.2024.100749","DOIUrl":null,"url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Assessment</div></div><div><h3>Case Presentation</h3><div>A 66-year-old female with hyperlipidemia was referred to cardiology due to a family history of coronary artery disease (CAD). Prior to her initial visit, she had a total cholesterol (TC) 264 mg/dL, triglycerides (TG) 89 mg/dL, high-density lipoprotein (HDL) 76mg/dL, and low-density lipoprotein (LDL) 173 mg/dL; her lipoprotein (a) was 314.4 nmol/L. She had undergone Commuted Tomography (CT) Coronary Artery Calcium Score (CACS) testing and had an Agatston calcium score of 5.6 (57th percentile). Her weight was 66 kg with a BMI of 25.7 kg/m2. She was initiated on pravastatin 20 mg and her LDL improved to 70 mg/dL, however she began to note weight gain. She was switched to rosuvastatin 20 mg and noted a profound lack of satiety, with a further 4kg total weight gain since statin initiation seven months prior, while her LDL improved to 44 mg/dL. She was switched to evolocumab, and her lack of satiety improved immediately. She lost 3 kg within three months of stopping her statin.</div></div><div><h3>Background</h3><div>Dyslipidemia is a primary risk factor for atherosclerotic cardiovascular disease, and a target of preventative cardiology. Prior studies have shown that statin users may adopt a less heart-healthy diet while on a statin, due to a belief of being protected from bad outcomes, ultimately resulting in more weight gain. However, even in those making favorable lifestyle choices, statins may be a hindrance to their goals of weight loss though a leptin-mediated impairment of satiety.</div></div><div><h3>Conclusions</h3><div>Anecdotal evidence has demonstrated weight gain as a frequent side effect of statin use. This case illustrates a clear temporal relationship between statin use and weight gain, primarily mediated by a lack of satiety. While statins may address one element of primary prevention, in some patients, they may contribute to another, and alternative agents should be used. Further studies are needed to better understand the mechanism behind this effect.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266666772400117X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Therapeutic Area

ASCVD/CVD Risk Assessment

Case Presentation

A 66-year-old female with hyperlipidemia was referred to cardiology due to a family history of coronary artery disease (CAD). Prior to her initial visit, she had a total cholesterol (TC) 264 mg/dL, triglycerides (TG) 89 mg/dL, high-density lipoprotein (HDL) 76mg/dL, and low-density lipoprotein (LDL) 173 mg/dL; her lipoprotein (a) was 314.4 nmol/L. She had undergone Commuted Tomography (CT) Coronary Artery Calcium Score (CACS) testing and had an Agatston calcium score of 5.6 (57th percentile). Her weight was 66 kg with a BMI of 25.7 kg/m2. She was initiated on pravastatin 20 mg and her LDL improved to 70 mg/dL, however she began to note weight gain. She was switched to rosuvastatin 20 mg and noted a profound lack of satiety, with a further 4kg total weight gain since statin initiation seven months prior, while her LDL improved to 44 mg/dL. She was switched to evolocumab, and her lack of satiety improved immediately. She lost 3 kg within three months of stopping her statin.

Background

Dyslipidemia is a primary risk factor for atherosclerotic cardiovascular disease, and a target of preventative cardiology. Prior studies have shown that statin users may adopt a less heart-healthy diet while on a statin, due to a belief of being protected from bad outcomes, ultimately resulting in more weight gain. However, even in those making favorable lifestyle choices, statins may be a hindrance to their goals of weight loss though a leptin-mediated impairment of satiety.

Conclusions

Anecdotal evidence has demonstrated weight gain as a frequent side effect of statin use. This case illustrates a clear temporal relationship between statin use and weight gain, primarily mediated by a lack of satiety. While statins may address one element of primary prevention, in some patients, they may contribute to another, and alternative agents should be used. Further studies are needed to better understand the mechanism behind this effect.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体重增加与食欲:他汀类药物对初级预防的双刃效应
治疗领域心血管疾病/心血管疾病风险评估病例介绍一位 66 岁的女性高脂血症患者因有冠状动脉疾病(CAD)家族史而被转诊至心脏科。初诊前,她的总胆固醇(TC)为 264 mg/dL,甘油三酯(TG)为 89 mg/dL,高密度脂蛋白(HDL)为 76 mg/dL,低密度脂蛋白(LDL)为 173 mg/dL;脂蛋白(a)为 314.4 nmol/L。她接受了计算机断层扫描(CT)冠状动脉钙化评分(CACS)检测,阿加斯顿钙化评分为 5.6(第 57 百分位数)。她的体重为 66 公斤,体重指数为 25.7 公斤/平方米。她开始服用普伐他汀 20 毫克,低密度脂蛋白改善到 70 毫克/分升,但体重开始增加。她转而服用罗伐他汀 20 毫克后,发现严重缺乏饱腹感,自 7 个月前开始服用他汀类药物以来,体重又增加了 4 千克,而低密度脂蛋白则降至 44 毫克/分升。她改用了依维莫司后,饱腹感立即得到改善。背景血脂异常是动脉粥样硬化性心血管疾病的主要危险因素,也是心脏病预防的目标之一。先前的研究表明,他汀类药物使用者在服用他汀类药物期间,由于相信可以避免不良后果,可能会采用不太有益于心脏健康的饮食,最终导致体重增加。结论轶事证据表明,体重增加是使用他汀类药物的常见副作用。本病例表明,他汀类药物的使用与体重增加之间存在明显的时间关系,而体重增加主要是由缺乏饱腹感引起的。虽然他汀类药物可以解决一级预防的一个因素,但对某些患者来说,它可能会导致另一个因素,因此应使用替代药物。要更好地了解这种效应背后的机制,还需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
期刊最新文献
Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer Lipoprotein (a) testing patterns among subjects with a measured lipid panel: The Mayo Clinic experience Neutrophil-to-High-Density Lipoprotein Ratio (NHR) and Neutrophil-to-Lymphocyte Ratio (NLR) as prognostic biomarkers for incident cardiovascular disease and all-cause mortality: A comparison study Genetic risk score for coronary artery calcification and its predictive ability for coronary artery disease Sex, ethnicity and language differences in statin prescribing in community health center patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1